Organisation paid for research Program year 2025 Source: CMS Open Payments

Josephson Wallack Munshower Neurology

Neither a doctor nor a teaching hospital

Research payments

$13,986,546

154 payments

Through program year 2025, Josephson Wallack Munshower Neurology is reported as receiving $13,986,546 in research payments, across 154 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,104,899	19
2024	Research	$1,606,881	36
2023	Research	$1,761,251	17
2022	Research	$2,740,824	18
2021	Research	$1,801,938	33
2020	Research	$901,872	18
2019	Research	$1,068,880	13

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $8,311,710 88 payments
Novartis Pharmaceuticals Corporation $5,293,371 22 payments
AbbVie, Inc. $143,276 15 payments
Amgen Inc. $134,810 19 payments
Biogen, Inc. $94,001 1 payment
Adamas Pharmaceuticals, Inc. $8,609 8 payments
Allergan Inc. $768 1 payment

Studies the money was for Research payments · program years 2019–2025

An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $4,941,710 9 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $2,642,457 9 payments
Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (Trailblazer-Real US) $2,621,101 3 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $646,914 2 payments
Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $538,989 4 payments
Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $264,078 5 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $245,238 6 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $207,974 2 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $183,555 5 payments
A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $174,949 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.